GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Short Interest

H. Lundbeck AS (LTS:0ND5) Short Interest


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of H. Lundbeck AS's Short Interest

For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

H. Lundbeck AS's Short Interest Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Short Interest distribution charts can be found below:

* The bar in red indicates where H. Lundbeck AS's Short Interest falls into.


H. Lundbeck AS (LTS:0ND5) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (LTS:0ND5) » Definitions » Short Interest
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA TSE:4507 VTRS NBIX XSWX:SDZ SZSE:000538 BOM:500124 BOM:532321 TSE:4523 HKSE:03692 BOM:543904 NSE:DIVISLAB NSE:TORNTPHARM CTLT
Traded in Other Exchanges
HLBBF:USA HLUBF:USA 0ABR:UK HLUN A:Denmark HLUN B:Denmark LDBA:Germany
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system, or CNS, drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.

H. Lundbeck AS (LTS:0ND5) Headlines

No Headlines